Q-omics provides the consensus-scored PDSS2 profile across patient tissues and cancer cell-line models. PDSS2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PDSS2 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, PDSS2 RNA expression shows 19,286 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where PDSS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDSS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDSS2 survival associations across molecular data types. PDSS2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDSS2 RNA expression–survival associations across cancer types. High PDSS2 expression shows favorable associations in KIRC, READ, KIRP, UCS, COAD and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PDSS2 RNA expression.
This table summarizes PDSS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PDSS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDSS2 shows lower tumor expression in KICH, KIRC, KIRP and THCA and higher tumor expression in STAD and CHOL. The KICH box plot shows higher PDSS2 RNA expression in normal versus tumor tissue (log2 FC = −1.518, t-test p < 0.001).
This table shows molecular features associated with PDSS2 in patient tissues and cancer cell lines. In patient samples, PDSS2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDSS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
